本文選題：氣機(jī)升降 + 隊(duì)列研究　； 參考：《北京中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:觀察花寶金教授運(yùn)用中西醫(yī)結(jié)合治療化療敏感的小細(xì)胞肺癌患者,對總生存期(Overall survival,OS)、無進(jìn)展生存時(shí)間(progression-free survival,PFS)的影響,分析中醫(yī)藥在整體治療過程中介入的合適時(shí)機(jī),并對應(yīng)用的方藥進(jìn)行討論分析,為小細(xì)胞肺癌患者的治療提供依據(jù)和幫助。方法:本研究采用探索性的隊(duì)列研究模式,納入2013年10月一2015年12月期間就診于中國中醫(yī)科學(xué)院廣安門醫(yī)院及中國醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院的初治的門診小細(xì)胞肺癌患者。根據(jù)是否接受中醫(yī)藥治療為暴露因素,分為中西醫(yī)結(jié)合隊(duì)列和西醫(yī)隊(duì)列。研究總共納入70例病例,脫落5例,最終完成治療并納入統(tǒng)計(jì)的共65例。其中,中西醫(yī)結(jié)合隊(duì)列組34例,包括局限期25例,廣泛期9例;西醫(yī)隊(duì)列組31例,包括局限期20例,廣泛期11例。西醫(yī)隊(duì)列采用EP/CE的一線化療方案,治療至少4-6周期,并結(jié)合患者實(shí)際情況施行放療及預(yù)防性全腦放療,中西醫(yī)隊(duì)列西醫(yī)治療同西醫(yī)隊(duì)列,中醫(yī)治療依據(jù)辨證要素不同及西醫(yī)治療階段不同予以系列方藥。氣虛證:組方以黃芪、白術(shù)、茯苓、陳皮為基礎(chǔ)加減;陰虛證:組方以北沙參、麥冬為基礎(chǔ)加減;痰濕證:組方以瓜蔞、薤白、半夏為基礎(chǔ)加減;血瘀證:組方以桃仁、赤芍、枳殼、桔梗、柴胡、川芎為基礎(chǔ)加減;熱毒證:組方以麻黃、生石膏、杏仁為基礎(chǔ)加減。化療階段:多選用旋覆花、代赭石、半夏、黃連、熟地、山萸肉、阿膠、鹿角霜等中藥辨證隨癥加減;放療階段:多選用瓜蔞、薤白、北沙參、麥冬、桔梗、荷梗、蘇梗、麻黃、生石膏、杏仁等中藥辨證隨癥加減;維持治療階段:多選用黃芪、白術(shù)、茯苓、陳皮、天麻、鉤藤、石決明、酒大黃、姜黃、僵蠶、蟬蛻等中藥辨證隨癥加減。4-6周期化療后進(jìn)入隨訪階段。研究的主要終點(diǎn)指標(biāo)包括OS、PFS、1年生存率、2年生存率、半年疾病無進(jìn)展率、1年疾病無進(jìn)展率、2年疾病無進(jìn)展率;次要指標(biāo)包括實(shí)體瘤療效評價(jià)、中醫(yī)癥狀評分改善情況、KPS評分變化情況以及NCI不良反應(yīng)等。另外,本研究將中藥介入的時(shí)機(jī)對PFS的影響納入也列入觀察,并對應(yīng)用的方藥進(jìn)行討論分析。結(jié)果:1生存分析:(1)中西醫(yī)隊(duì)列組與西醫(yī)隊(duì)列組的中位總生存期(Median Survival Time,MST)分別為24和20個(gè)月(P=0.221),1年、2年的累計(jì)生存率分別為94.1%、64.7%和80.6%、51.6%。經(jīng)分層研究,局限期中西醫(yī)隊(duì)列組與西醫(yī)隊(duì)列組的MST分別為25和22個(gè)月(P=0.656),1年、2年的累計(jì)生存率分別為96.0%、48.0%和85.0%、35.0%;廣泛期中西醫(yī)隊(duì)列組與西醫(yī)隊(duì)列組的MST分別為21和16個(gè)月(P=0.632),1年、2年的累計(jì)生存率分別為88.9%、22.2%和72.7%、18.2%。(2)中西醫(yī)隊(duì)列組與西醫(yī)隊(duì)列組的中位無進(jìn)展生存時(shí)間(Median Progression Free Survival,mPFS)分別為19和14個(gè)月(P=0.098),半年、1年、2年無進(jìn)展率分別為91.2%、70.6%、44.1%和74.2%、51.6%、29.0%。經(jīng)分層研究,局限期中西醫(yī)結(jié)合隊(duì)列與西醫(yī)隊(duì)列比較,mPFS分別為19和15個(gè)月(P=0.421),半年無進(jìn)展率分別為96.0%、85.0%,1年無進(jìn)展率分別為80.0%、60.0%,2年無進(jìn)展率分別為48.0%、35.0%;廣泛期中西醫(yī)結(jié)合隊(duì)列與西醫(yī)隊(duì)列比較,mPFS分別為11和7個(gè)月(P=0.289),半年無進(jìn)展率分別為77.8%、54.5%,1年無進(jìn)展率分別為44.4%、36.4%,2年無進(jìn)展率分別為33.3%、18.2%。(3)將中西醫(yī)隊(duì)列按照中藥介入時(shí)間的不同分組,分為診斷后6個(gè)月以內(nèi)介入中藥組與超過6個(gè)月時(shí)間介入中藥組。兩組mPFS分別為24和19個(gè)月(P=0.809)。(4)以60歲為界,小于60歲與大于60歲的MST分別為25和21個(gè)月,差異具有統(tǒng)計(jì)學(xué)意義(P=0.002)。(5)按性別不同分組,男性和女性的MST分別為22和24個(gè)月(P=0.904)。(6)按KPS評分不同分組,KPS70分、80分、90分三組MST分別為12、22和25個(gè)月。KPS70分與80分相比,差異具有統(tǒng)計(jì)學(xué)意義(P=0.000);KPS70分與90分相比,差異具有統(tǒng)計(jì)學(xué)意義(P=0.001);KPS80分與90分相比,差異不具有統(tǒng)計(jì)學(xué)意義(P=0.492)。(7)按化療方式不同分組,單純化療、序貫、夾心及同步放化療的MST分別為20、22、24和32個(gè)月,單純化療與其他各組比較,差異均具有統(tǒng)計(jì)學(xué)意義(P值分別為0.038、0.042和0.026)。(8)按施行PCI的情況分組,施行PCI治療與未行PCI治療的MST分別為 32 和 20 個(gè)月(P=0.006)。2預(yù)后分析:進(jìn)入Cox比例風(fēng)險(xiǎn)模型的預(yù)后因素分別是隊(duì)列、年齡、KPS評分、PCI情況,Wald 值分別為 3.643、7.004、4.578、8.811,回歸系數(shù)分別為-0.595、0.859、-1.320、-1.008,相對危險(xiǎn)度分別為 0.551、2.361、0.267、0.365,P 值分別為 0.056、0.008、0.032、0.003。3實(shí)體瘤療效:療后42天、84天,兩組的總有效率(Overall Response Rate,ORR)無統(tǒng)計(jì)學(xué)差異(P0.05),但在療后126天,兩組ORR相比P=0.052。療后42天,兩組的腫瘤疾病控制率(Disease Control Rate,DCR)無統(tǒng)計(jì)學(xué)差異(P0.05),但在療后84天、126天,兩組DCR具有統(tǒng)計(jì)學(xué)差異(P值分別為0.015和0.031)。4 KPS評分變化:療后42天、84天、126天KPS評分變化情況,中西醫(yī)隊(duì)列和西醫(yī)隊(duì)列比較,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05)。5中醫(yī)臨床癥狀療效比較:對治療前后中醫(yī)臨床癥狀療效評價(jià)情況作比較,中西醫(yī)隊(duì)列組與西醫(yī)隊(duì)列組差異具有統(tǒng)計(jì)學(xué)意義(P=0.0l0),并對癥狀量表進(jìn)行分析,結(jié)果發(fā)現(xiàn)在改善神疲乏力、氣短、食欲不振、自汗盜汗、口干咽燥、胸悶、咳嗽、咯痰、便秘等9個(gè)癥狀方面,中西醫(yī)隊(duì)列與西醫(yī)隊(duì)列相比,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)6 NCI不良反應(yīng)分析:在血液系統(tǒng)不良反應(yīng)方面,白細(xì)胞和血小板減少不良反應(yīng),兩隊(duì)列相比,差異不具有統(tǒng)計(jì)學(xué)意義(P0.05),在中性粒細(xì)胞及血紅蛋白減少不良反應(yīng)方面,兩隊(duì)列相比,差異具有統(tǒng)計(jì)學(xué)意義(P值分別為0.008和0.008);在消化系統(tǒng)不良反應(yīng)各方面,兩隊(duì)列差異均不具有統(tǒng)計(jì)學(xué)意義(P0.05);在泌尿系統(tǒng)不良反應(yīng)方面,肌酐不良反應(yīng),差異具有統(tǒng)計(jì)學(xué)意義(P=0.032)。7研究方藥討論分析:依據(jù)辨證要素不同及西醫(yī)治療階段不同予以的系列方藥,利用了藥物的升降浮沉及性味歸經(jīng),在疾病發(fā)展及西醫(yī)治療的不同階段中針對用藥,升清降濁,以使肺癌發(fā)生所涉臟腑順應(yīng)其各自的生理特性,氣機(jī)升降恢復(fù)平衡,從而改善機(jī)體持續(xù)存在的惡性環(huán)境。結(jié)論:1初治的小細(xì)胞患者年齡不超過60歲、KPS評分高于70分,施行PCI治療是影響小細(xì)胞肺癌生存的3個(gè)有益因素。2花寶金教授運(yùn)用以氣機(jī)升降為指導(dǎo)的中藥治療配合西醫(yī)治療較單純西醫(yī)治療,可以改善化療敏感的小細(xì)胞肺癌患者體力狀況,緩解臨床癥狀以及減輕血液系統(tǒng)和泌尿系統(tǒng)的不良反應(yīng)。在延長OS、PFS方面有一定作用,并提示中藥早期介入可能效果更佳,需擴(kuò)大樣本量以驗(yàn)證。
[Abstract]:Objective: To observe the effect of the combination of Chinese and Western Medicine on the treatment of chemotherapy sensitive small cell lung cancer patients with chemotherapy sensitive small cell lung cancer, the effect of Overall survival (OS) and progression-free survival, PFS). Methods: This study adopted an exploratory cohort study into the early treatment of small cell lung cancer patients in the Guanganmen Hospital of Chinese Academy of traditional Chinese medicine (Chinese Academy of Chinese Medicine) and the Cancer Hospital of the Chinese Academy of Medical Sciences in December 2015 October 2013. The exposure factors were divided into the combination of Chinese and Western medicine and the western medicine cohort. A total of 70 cases were included, 5 cases were dropped out, and the final treatment was completed in a total of 65 cases. Among them, 34 cases of integrated traditional Chinese and Western medicine group, including 25 cases of limited period, 9 cases extensively, 31 cases in the western medicine cohort, 20 cases in the inclusion Bureau, 11 in the extensive period, and EP/CE in the western medicine cohort. The first line chemotherapy regimen was treated at least 4-6 cycles, combined with the actual situation of the patients to carry out radiotherapy and preventive whole brain radiotherapy. Western medicine and Western medicine were used to treat the same Western medicine cohort. Traditional Chinese medicine treatment was based on different syndrome differentiation factors and different Western medicine treatment stages. Qi deficiency syndrome: the group was based on Astragalus, Atractylodes, Poria, and Pericarpium, and yin deficiency. Syndrome: the group with Radix Ophiopogon and Radix Ophiopogon as basic addition and subtraction, phlegm dampness syndrome: group with Trichosanthes, Allium scallion and Pinellia ternate; blood stasis syndrome: group with peach kernel, radix paeoniae rubra, Fructus aurantii, Radix Bupleuri, Ligusticum chuanxiong as basic addition and subtract; heat toxin syndrome: group with ephedra, gypsum and almond as the basis. The TCM syndrome differentiation and subtraction of Chinese herbal medicine, such as Cornus meat, Ejiao, antler frost, and other TCM syndrome differentiation, and radiotherapy stage: multiple selection of Trichosanthes, Allium macrostemon, Radix Ophiopogon, Rhizoma Ophiopogon, rhizome, ephedra, apricot kernel and other TCM syndrome differentiation and reduction; maintenance treatment stage: more selection of Astragalus, Atractylodes, tuckahoe, Chen peel, Gastrodia elata, rhubarb, rhubarb, turmeric, silkworm, cicada and other Chinese Medicine The main end points of the study were OS, PFS, 1 year survival rate, 2 year survival rate, six year disease progression rate, 1 year disease free progression rate, 1 year disease free progression rate, 2 year disease free progression rate, and secondary indexes including solid tumor evaluation, improvement of TCM symptom score, KPS score, and NCI did not. In addition, the effect of the timing of the intervention of traditional Chinese medicine on PFS was also included, and the application of the prescription was discussed and analyzed. Results: 1 Survival Analysis: (1) the median total survival period (Median Survival Time, MST) of the Chinese and Western medicine cohort group and the western medicine cohort were 24 and 20 months (P=0.221), 1 years, and 2 years' cumulative survival rate. Don't be 94.1%, 64.7%, and 80.6%. 51.6%. was studied by stratification. The MST of the traditional Chinese and Western medicine cohort and the western medicine cohort were 25 and 22 months (P=0.656), 1 years and 2 years were 96%, 48% and 85%, 35%, respectively. The extensive period of Chinese and Western Medicine cohort and the western medicine cohort were respectively 21 and 16 months (P=0.632), 1 years, and the cumulative birth years. The survival rates were 88.9%, 22.2% and 72.7% respectively. 18.2%. (2) the middle and Western medicine queue group and the western medicine queue group were 19 and 14 months (P=0.098), respectively, 19 and 14 months (P=0.098), half a year, 1 years, and 2 years, respectively, 91.2%, 70.6%, 44.1% and 74.2%, 51.6%, 29.0%. through stratified study, limited period and Western medicine team. Compared with the western medicine cohort, mPFS was 19 and 15 months (P=0.421) respectively. The non progress rate of half a year was 96%, 85%, and 1 year progression free rate was 80%, 60% and 35%, respectively, 48% and 35%, respectively. Compared with the western medicine cohort, mPFS was divided into 11 and 7 months (P=0.289), and the half year progression rate was 77.8%, respectively. The rate of no progress in 1 years was 44.4%, 36.4%, and 2 years, respectively, 33.3%. 18.2%. (3) divided the Chinese and Western medicine queues according to the different intervention time of Chinese medicine, divided into 6 months after the diagnosis and more than 6 months to intervene the traditional Chinese medicine group. The two group mPFS was 24 and 19 months (4) respectively. (4) with 60 years as the boundary, less than 60 and greater than those. MST was 25 and 21 months, respectively, and the difference was statistically significant (P=0.002). (5) according to gender differences, the MST of men and women were 22 and 24 months (P=0.904). (6) according to the KPS score, the differences were statistically significant (P=0.000), KPS70, 80, 90 and 25 months.KPS70 and 25 months respectively (P=0.000); KPS70 score. Compared with 90 points, the difference was statistically significant (P=0.001). Compared with 90 points, the difference was not statistically significant (P=0.492). (7) the differences were statistically significant (P value points) compared with other groups according to the different groups of chemotherapy, the MST of simple chemotherapy, sequential, sandwich and concurrent chemoradiotherapy were 20,22,24 and 32 months respectively. 0.038,0.042 and 0.026). (8) groups according to the implementation of PCI, the MST of the PCI treatment and the non PCI treatment was 32 and 20 months (P=0.006).2, respectively. The prognostic factors of the Cox proportional hazard model were the cohort, the age, the KPS score, the PCI, the Wald was 3.643,7.004,4.578,8.811, and the regression coefficients were respectively 95,0.859, -1.320, -1.008, relative risk was 0.551,2.361,0.267,0.365, P value was 0.056,0.008,0.032,0.003.3 solid tumor respectively: 42 days, 84 days after treatment, the total effective rate of two groups (Overall Response Rate, ORR) was not statistically significant (P0.05), but 126 days after the treatment, two groups of ORR compared with the two group of cancer control 42 days after treatment. Disease Control Rate (DCR) had no statistical difference (P0.05), but at 84 days and 126 days after treatment, the two groups of DCR had statistical difference (P value 0.015 and 0.031).4 KPS score changes: 42 days after treatment, 84 days, 126 days KPS score changes, the difference was statistically significant (P0.05).5 traditional Chinese medicine clinical symptoms (P0.05). Comparison of curative effect: the comparison of the clinical symptoms and symptoms of traditional Chinese medicine before and after treatment, the difference between the Chinese and Western medicine queue group and the western medicine queue group had statistical significance (P=0.0l0), and the symptom scale was analyzed. The results were found in the improvement of fatigue, shortness of breath, loss of appetite, sweating and sweating, dry mouth dryness, chest tightness, cough, phlegm, constipation, and other 9 symptoms. Compared with the western medicine cohort, the difference was statistically significant (P0.05) 6 NCI adverse reaction analysis: in the side effects of the blood system, leukocytes and thrombocytopenia decreased adverse reactions, and the differences were not statistically significant (P0.05). The two teams decreased the adverse reactions in neutrophils and hemoglobin. The difference was statistically significant (P value was 0.008 and 0.008), and the differences in the adverse reactions of the digestive system were not statistically significant (P0.05); the adverse reaction of the urinary system, the adverse reaction of the creatinine, was statistically significant (P=0.032) the analysis of the.7 research prescription: according to the differentiation of syndrome differentiation factors and the West A series of prescriptions which are different at the stage of medical treatment have made use of the rise and fall of the drugs and the sexual taste to the meridian. In the different stages of the disease development and the different stages of the western medicine treatment, the medicine should be raised to reduce the turbidity, so that the organs involved in the lung cancer should conform to their respective physiological characteristics, the Qi and the Qi can be restored and balanced, so as to improve the persistent malignant environment of the body. The age of 1 primary treatment of small cell patients is not more than 60 years old, KPS score is higher than 70. PCI treatment is the 3 beneficial factor affecting the survival of small cell lung cancer..2 Hua Bao Jin is treated with western medicine treatment in combination with western medicine, which is guided by the lifting of air machine, and can improve the physical condition of patients with chemotherapy sensitive small cell lung cancer. Alleviate the clinical symptoms and reduce the adverse reactions of the blood system and the urinary system. It has a certain role in prolonging the OS and PFS, and suggests that the early intervention of Chinese medicine may be better, and the sample size should be expanded to verify.

【學(xué)位授予單位】：北京中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 金炳文,趙蘭,周彩存,李德仁,徐建芳;神經(jīng)元特異性烯醇化酶檢測在小細(xì)胞肺癌預(yù)后中的價(jià)值[J];中華結(jié)核和呼吸雜志;2001年12期

2 王云杰,趙正源,劉錕;小細(xì)胞肺癌治療的回顧與展望[J];陜西腫瘤醫(yī)學(xué);2001年03期

3 李勇 ,黃瑞文;小兒小細(xì)胞肺癌1例[J];臨床腫瘤學(xué)雜志;2002年01期

4 周濤 ,劉素勤 ,劉基巍;小細(xì)胞肺癌脊髓及馬尾轉(zhuǎn)移1例[J];臨床腫瘤學(xué)雜志;2002年01期

5 徐長明 ,劉長軍 ,袁繼彬;12例小細(xì)胞肺癌早期X線表現(xiàn)[J];現(xiàn)代醫(yī)藥衛(wèi)生;2002年03期

6 宋元龍,李高峰,巫正偉;76例小細(xì)胞肺癌綜合治療分析[J];云南醫(yī)藥;2002年04期

7 羅文軍,殷富春,郭偉;小細(xì)胞肺癌誤診1例報(bào)告[J];實(shí)用放射學(xué)雜志;2003年12期

8 歐陽瑤 ,鄧飛 ,劉華慶;小細(xì)胞肺癌中血小板衍生生長因子的表達(dá)及意義[J];貴州醫(yī)藥;2003年01期

9 張毅,顧艷斐,鄧立宏,楊聲,李世業(yè);小細(xì)胞肺癌508例不同治療方式的綜合評價(jià)[J];中華醫(yī)學(xué)雜志;2004年11期

10 毛娟華;小細(xì)胞肺癌40例臨床分析[J];中國腫瘤;2004年07期

相關(guān)會議論文 前10條

1 王潔;;小細(xì)胞肺癌規(guī)范化治療及其最新進(jìn)展[A];第三屆中國腫瘤內(nèi)科大會教育集暨論文集[C];2009年

2 王華慶;李蘭芳;;小細(xì)胞肺癌的內(nèi)科治療及進(jìn)展[A];第三屆中國腫瘤學(xué)術(shù)大會教育論文集[C];2004年

3 尹秋霞;;神經(jīng)元特異性烯醇化酶測定對小細(xì)胞肺癌的診斷價(jià)值[A];中國免疫學(xué)會第五屆全國代表大會暨學(xué)術(shù)會議論文摘要[C];2006年

4 傅小龍;;小細(xì)胞肺癌治療的共識和爭議[A];2007第六屆全國放射腫瘤學(xué)學(xué)術(shù)年會論文集[C];2007年

5 吳殷;曲亞偉;陳宗越;;小細(xì)胞肺癌選擇性支氣管動(dòng)脈灌注化療近期療效分析(摘要)[A];中華醫(yī)學(xué)會第六屆全國結(jié)核病學(xué)術(shù)大會論文匯編[C];2000年

6 萬會平;;小細(xì)胞肺癌治療進(jìn)展[A];江西省中醫(yī)藥學(xué)會2011年學(xué)術(shù)年會論文集[C];2011年

7 丁小青;蔣留留;張志堅(jiān);王梅;許文榮;朱偉;錢暉;;轉(zhuǎn)移性人小細(xì)胞肺癌裸鼠模型的建立[A];中華醫(yī)學(xué)會第七次全國中青年檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)會議論文匯編[C];2012年

8 程穎;柳菁菁;;小細(xì)胞肺癌內(nèi)科治療的探索[A];第13屆全國肺癌學(xué)術(shù)大會論文匯編[C];2013年

9 張軍;李厚文;;化療、放療,加顱腦預(yù)防性放射,治愈晚期小細(xì)胞肺癌[A];第13屆全國肺癌學(xué)術(shù)大會論文匯編[C];2013年

10 茍?zhí)m英;安社娟;嚴(yán)紅虹;吳一龍;;基于509例系列患者分析小細(xì)胞肺癌的治療現(xiàn)狀[A];第13屆全國肺癌學(xué)術(shù)大會論文匯編[C];2013年

相關(guān)重要報(bào)紙文章 前10條

1 鮑云華;小細(xì)胞肺癌有了新標(biāo)志物[N];健康報(bào);2003年

2 朱立明;“套餐式”療法使小細(xì)胞肺癌患者獲益[N];中國醫(yī)藥報(bào);2007年

3 劉霞;新藥物可抑制小細(xì)胞肺癌細(xì)胞[N];科技日報(bào);2009年

4 實(shí)習(xí)生 程鳳;小細(xì)胞肺癌擴(kuò)散與基因缺失相關(guān)[N];科技日報(bào);2011年

5 中華胸心血管外科學(xué)會肺癌學(xué)組組長 支修益;小細(xì)胞肺癌 不容忽視的20%[N];健康報(bào);2013年

6 陳青;敢對小細(xì)胞肺癌動(dòng)刀[N];文匯報(bào);2003年

7 賀用和 董海濤 林紅生;小細(xì)胞肺癌132例中西醫(yī)結(jié)合治療臨床總結(jié)[N];中國中醫(yī)藥報(bào);2004年

8 中華胸心血管外科學(xué)會肺癌學(xué)組組長 支修益;ProGRP檢測助力小細(xì)胞肺癌管理[N];中國醫(yī)藥報(bào);2013年

9 常怡勇;吸煙者突然厭煙當(dāng)心肺癌[N];中國中醫(yī)藥報(bào);2006年

10 唐夏;吸煙低齡化導(dǎo)致肺癌低齡化[N];中國消費(fèi)者報(bào);2007年

相關(guān)博士學(xué)位論文 前10條

1 王平;小細(xì)胞肺癌個(gè)體化放射治療方案的優(yōu)化[D];天津醫(yī)科大學(xué);2015年

2 姜威;凋亡通路基因的MicroRNA相關(guān)單核苷酸多態(tài)性與局限期小細(xì)胞肺癌預(yù)后的關(guān)聯(lián)研究和調(diào)強(qiáng)放療與三維適形放療技術(shù)對局部晚期非小細(xì)胞肺癌放射性肺損傷影響的臨床研究[D];北京協(xié)和醫(yī)學(xué)院;2016年

3 王希明;人附睪蛋白4(HE4)作為新型腫瘤標(biāo)志物在小細(xì)胞肺癌應(yīng)用的初步研究[D];第四軍醫(yī)大學(xué);2016年

4 吳紅波;沉默SURVIVIN抑制小細(xì)胞肺癌細(xì)胞增殖和逆轉(zhuǎn)化療耐藥性研究[D];鄭州大學(xué);2016年

5 陳駿;小細(xì)胞肺癌的預(yù)后因素[D];中國醫(yī)科大學(xué);2009年

6 王淳;胎盤生長因子在小細(xì)胞肺癌細(xì)胞穿過血腦屏障中的作用[D];中國醫(yī)科大學(xué);2007年

7 朱慧;放射治療對小細(xì)胞肺癌預(yù)后的影響[D];北京協(xié)和醫(yī)學(xué)院;2011年

8 蘇景偉;小細(xì)胞肺癌綜合治療療效分析及相關(guān)腫瘤標(biāo)記物的研究[D];河北醫(yī)科大學(xué);2012年

9 趙漢璽;表沒食子兒茶素沒食子酸酯用于小細(xì)胞肺癌的基礎(chǔ)及臨床研究[D];山東大學(xué);2012年

10 張文玨;小細(xì)胞肺癌的綜合治療及預(yù)后因素研究[D];北京協(xié)和醫(yī)學(xué)院;2015年

相關(guān)碩士學(xué)位論文 前10條

1 俞波;小細(xì)胞肺癌伴抗利尿激素分泌不當(dāng)綜合征[D];山東大學(xué);2009年

2 楊光;小細(xì)胞肺癌腫瘤標(biāo)志物檢測的臨床意義[D];河北醫(yī)科大學(xué);2015年

3 梁珍;多西紫杉醇靶向納米藥物對小細(xì)胞肺癌治療作用的研究[D];北京協(xié)和醫(yī)學(xué)院;2015年

4 趙傳多;Ⅱ-ⅢA期小細(xì)胞肺癌外科治療臨床研究[D];北京協(xié)和醫(yī)學(xué)院;2015年

5 何花;小細(xì)胞肺癌中毒蕈堿膽堿受體3的表達(dá)及意義[D];寧夏醫(yī)科大學(xué);2015年

6 趙維川;多指標(biāo)聯(lián)合檢測在小細(xì)胞肺癌診斷中的應(yīng)用價(jià)值研究[D];河北醫(yī)科大學(xué);2015年

7 臧婉娜;局限期小細(xì)胞肺癌不同治療模式的對比研究[D];河北醫(yī)科大學(xué);2015年

8 李治樺;小細(xì)胞肺癌二線化療方案療效分析及診斷和療效預(yù)測相關(guān)多肽的探索性研究[D];中國人民解放軍軍事醫(yī)學(xué)科學(xué)院;2015年

9 孔月;低鈉血癥與小細(xì)胞肺癌患者預(yù)后關(guān)系的研究[D];蘇州大學(xué);2015年

10 王靜;75例小細(xì)胞肺癌患者血液高凝狀態(tài)的臨床研究[D];山西醫(yī)科大學(xué);2015年

，

本文編號：1885675